CN112574330A - Crystal form of sugammadex sodium - Google Patents
Crystal form of sugammadex sodium Download PDFInfo
- Publication number
- CN112574330A CN112574330A CN201910928446.3A CN201910928446A CN112574330A CN 112574330 A CN112574330 A CN 112574330A CN 201910928446 A CN201910928446 A CN 201910928446A CN 112574330 A CN112574330 A CN 112574330A
- Authority
- CN
- China
- Prior art keywords
- sugammadex
- sodium
- degrees
- sugammadex sodium
- crystal form
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
- C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
- C08B37/0012—Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/724—Cyclodextrins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
The invention provides a sugammadex crystal form, and relates to the technical field of crystal form drug molecules. The sugammadex crystal form uses Cu-Kalpha radiation, and an X-ray diffraction spectrogram expressed by 2 theta shows that the crystal form has characteristic peaks at 4.49 +/-0.2 degrees, 5.47 +/-0.2 degrees, 7.20 +/-0.2 degrees, 7.77 +/-0.2 degrees, 8.80 +/-0.2 degrees, 9.96 +/-0.2 degrees, 10.24 +/-0.2 degrees, 12.54 +/-0.2 degrees, 15.75 +/-0.2 degrees, 16.28 +/-0.2 degrees, 16.85 +/-0.2 degrees, 17.59 +/-0.2 degrees, 18.06 +/-0.2 degrees and 19.16 +/-0.2 degrees; and provides related preparation method and application. The sugammadex sodium crystal form has good stability, the clarity and the color of the solution meet the raw material medicine standard of the injection, and the safety and the stability of the sugammadex sodium injection preparation are improved.
Description
Technical Field
The invention relates to the technical field of crystal form drug molecules, in particular to a sugammadex crystal form.
Background
Sugammadex Sodium (Sugammadex Sodium), chemical name octa-6-per-deoxy-6-per (2-carboxyethyl) thio-gamma-cyclodextrin Sodium salt, CAS number: 343306-79-6, the specific structural formula is as follows:
the sugammadex sodium is a novel muscle relaxant reversal agent, is firstly developed by Organon corporation in the Netherlands, is used for reversing the blocking effect of a conventionally used neuromuscular blocking drug rocuronium bromide or vecuronium bromide, and can immediately reverse the effect of rocuronium bromide used by adults and the effect of rocuronium bromide used by children and teenagers (2-17 years old). Sugammadex sodium is the first and only Selective Relaxation Binding Agent (SRBA), the first major drug development in the field of narcotics over 20 years, and is known as a milestone muscle relaxation antagonist.
Akzo Nobel owns a patent right on 6-mercaptocyclodextrin derivatives (publication No. CN1402737A), which was incorporated into Xianlingbao-ya, Mlingbao-ya and later developed sumamadex by Ougangong, Netherlands, the department of human health and health, in 2007, and was purchased by Miner Shadong, Mblend, in 2009. The product has been approved in the european union and japan in 2008 and 2010, respectively. Sodium sugammadex injection (trade name: Bridion) is approved by the FDA at 12 months and 15 days 2015 for sale.
In recent years, researches show that the crystal forms of the drugs are different, and the physicochemical properties (density, hardness, solubility, stability, optical property, electrical property and the like), dissolution rate, biological effect and the like of the drugs can be changed, so that the research on the crystal forms of the drugs has important practical value in medicine and pharmacology. The crystal form drug molecules comprise polymorphism, hydrate, solvate, salt and the like of the drug molecules, and through the way of drug crystallization, the crystallography parameters of the crystal form drug molecules can be determined, and the types and the number of the solvent molecules (such as crystal water molecules) in the crystal form can be determined, so that the crystal form drug molecules have very important effects on understanding and mastering the spatial arrangement and the physicochemical properties of the drug molecules.
In the current study report of the crystal form of sugammadex sodium, CN107400182 reports that alcohol such as methanol and ethanol is dripped into a sugammadex sodium aqueous solution to prepare a sugammadex sodium crystal form a; patent IN201741012475 reports that methanol is dripped into a methanol/water mixed solution for crystallization to obtain a sugammadex crystal form; patent US9879096 discloses the preparation of an amorphous form of sugammadex sodium; patent CN109053933 reports 5 sugammadex crystal forms and one sugammadex amorphous form, patent TW201912656 discloses sugammadex crystal forms I and II, and reports that sugammadex crystal form III is obtained by heating crystal form II to induce crystal transformation.
As is well known, sugammadex sodium as an effective muscle relaxant is an injection raw material drug, and an injection preparation has strict requirements on various aspects of the raw material drug, and the known sugammadex sodium crystal form cannot well meet the requirements of a pharmaceutical preparation in the aspects of clarity, color, solubility, thermal stability, photostability, dissolution rate, bioavailability and the like, so that more crystal forms need to be developed, on one hand, more sugammadex sodium crystal forms are provided for pharmaceutical application, and on the other hand, the pharmaceutical performance is improved in the aspects of chemical purity, fluidity, solubility, stability (such as storage stability, dehydration stability, polymorphic transformation stability, low hygroscopicity, low residual solvent content), clarity and the like, and a more efficient medicine is developed; on the other hand, the crystal form of sugammadex sodium which is more suitable for industrial production and has high economic benefit is also developed.
Disclosure of Invention
In order to overcome the disadvantages of the prior art, it is an object of the present invention to provide a crystalline form of sugammadex sodium; another object of the present invention is to provide a method for preparing the sugammadex sodium crystal form; still another object of the present invention is to provide a use of a crystalline form of sugammadex sodium for the preparation of a muscle relaxant antagonist medicament.
The specific technical scheme of the invention is as follows:
a sugammadex crystal form uses Cu-Kalpha radiation, and has characteristic peaks at 4.49 +/-0.2 degrees, 5.47 +/-0.2 degrees, 7.20 +/-0.2 degrees, 9.96 +/-0.2 degrees, 10.24 +/-0.2 degrees, 15.75 +/-0.2 degrees, 17.57 +/-0.2 degrees in an X-ray diffraction spectrogram expressed by 2 theta.
Preferably, the sugammadex sodium crystal form has characteristic peaks at 4.49 +/-0.2 degrees, 5.47 +/-0.2 degrees, 7.20 +/-0.2 degrees, 7.77 +/-0.2 degrees, 8.80 +/-0.2 degrees, 9.96 +/-0.2 degrees, 10.24 +/-0.2 degrees, 12.54 +/-0.2 degrees, 15.75 +/-0.2 degrees, 16.28 +/-0.2 degrees, 16.85 +/-0.2 degrees, 17.59 +/-0.2 degrees, 18.06 +/-0.2 degrees and 19.16 +/-0.2 degrees by using Cu-Ka radiation and an X-ray diffraction spectrum expressed by 2 theta.
Preferably, the sugammadex sodium crystal form, using Cu-ka radiation, has characteristic peaks according to the X-ray powder diffraction pattern shown in fig. 1.
The preparation method of the sugammadex sodium crystal form specifically comprises the following steps:
adding sugammadex sodium into purified water, stirring and dissolving to obtain a sugammadex sodium aqueous solution; slowly dripping an organic solvent A into the sodium sugamide aqueous solution, placing the sodium sugamide aqueous solution into a freeze dryer for pre-freezing, opening a cold trap after solidification, vacuumizing, slowly heating to a certain temperature for the first time, maintaining the temperature for sublimation drying, and finishing drying; slowly raising the temperature to a certain temperature for the second time, maintaining the temperature for analysis and drying, and closing the cold trap after drying to obtain white crystal sodium sulgamide.
Preferably, the mass-to-volume ratio of sugammadex sodium to purified water is 1: 4-6 g/ml.
Preferably, the organic solvent A is one or two of methanol, ethanol, isopropanol, acetone, n-butanol and acetonitrile; ethanol is preferred.
Preferably, the mass-volume ratio of the sugammadex sodium to the organic solvent A is 1: 0.5-1.5, g/ml.
Preferably, the prefreezing temperature is-50 to-30 ℃.
Preferably, the pre-freezing maintaining time is the time for completely solidifying the liquid, and is preferably 10-18 hours.
Preferably, the temperature is slowly increased to-25 to-10 ℃ for the first time; the heating rate is preferably 1 ℃/3-5 min.
Preferably, the sublimation drying maintaining time is 10-20 hours.
Preferably, the temperature is slowly raised to 0-10 ℃ for the second time; the heating rate is preferably 1 ℃/2-3 min.
Preferably, the desorption drying maintenance time is 15 to 20 hours.
The invention carries out the step of vacuumizing, and the subsequent drying step is carried out when the vacuum degree reaches more than 100 mT; the vacuum condition of the invention is preferably 100-200 mT; particularly preferably 150 mT.
The sugammadex sodium crystal form is used as an active ingredient for preparing a muscle relaxation antagonist drug.
An injection preparation, which contains the sugammadex sodium crystal form of the invention and other components.
Preferably, the preparation method of the injection preparation of the present invention is as follows: the compounds of the present invention are formulated for injection into a pharmaceutically acceptable solid or liquid carrier, and optionally with pharmaceutically acceptable excipients, using standard and conventional techniques.
Preferably, the preparation can be a ready-to-use liquid injection or a freeze-dried powder injection.
Preferably, the other components of the formulation include other active ingredients, osmotic pressure regulators, pH regulators, solubilizers, solubilizing agents, co-solvents, antioxidants, bacteriostats, emulsifiers, complexing agents, and the like, which may be used in combination.
More preferably, the osmotic pressure regulator is selected from one or more of sodium chloride, glucose, fructose, glycerol, sorbitol, xylitol, magnesium chloride, phosphate, sodium citrate and mannitol; the pH value regulator is selected from one or more of hydrochloric acid, sulfuric acid, lactic acid, malic acid, acetic acid, citric acid, phosphoric acid, sodium hydroxide, sodium carbonate, sodium bicarbonate, disodium hydrogen phosphate, sodium dihydrogen phosphate, sodium citrate and arginine; the solubilizer is selected from one or more of tween 80, tween 60 and poloxamer 68; the cosolvent is selected from sodium benzoate, sodium salicylate, sodium p-aminobenzoate, urethane, urea, erucamide, glucose, meglumine, malic acid, methionine, glycine, arginine, nicotinamide, sodium bicarbonate, phenylalanine, and vitamin B6One or more of the above; the antioxidant is selected from one or more of L-cysteine hydrochloride, sodium sulfite, sodium bisulfite, propyl gallate, glutathione, sodium thiosulfate, thiourea, mercaptoacetic acid, sodium metabisulfite and vitamin B; the bacteriostatic agent is selected from one or more of the following components; the emulsifier is selected from one or more of lecithin, soybean lecithin, poloxamer 68, cholesterol and glycerol monooleate; the complexing agent is one or more selected from disodium ethylene diamine tetraacetate and calcium disodium ethylene diamine tetraacetate.
The invention has the beneficial effects that:
1. the preparation method of the sugammadex sodium crystal form is simple, the requirement on production equipment is low, and the obtained product has high purity and yield and is suitable for large-scale popularization and application.
2. The sugammadex sodium crystal form has better stability, and the dosage form prepared by the crystal form is beneficial to medicine storage and ensures the medicine effect.
3. The solution of the sugammadex sodium crystal form is qualified in clarity and color, and the safety and stability of the sugammadex sodium injection preparation are improved.
Drawings
FIG. 1: sugammadex sodium crystal form X-ray powder diffraction pattern.
FIG. 2: a differential scanning calorimetry (DSC/TGA) graph of the sugammadex sodium crystal form.
Detailed Description
The invention is further illustrated by the following examples. It should be properly understood that: the examples of the present invention are intended to be illustrative only and not to be limiting, and therefore, the present invention is intended to be simply modified within the scope of the present invention as claimed.
Materials used in the experiment: sugammadex sodium is available commercially and can also be prepared by reference to the prior art; all materials used in other experiments, which have not been indicated for their origin and specification, are commercially available, analytically pure or chemically pure.
The freeze dryer adopted by the invention is LABCONCO
TriadTM2.5L)。
The purity of the sugammadex sodium is measured by HPLC, and the chromatographic conditions are as follows:
a chromatographic column: phenomenex, Aqua-C18(2.0mm×150mm,3.0μm)；
Mobile phase: mobile phase A: 25.0mmol/L phosphate buffer (pH 3.0) (3.45 g sodium dihydrogen phosphate monohydrate taken in a 1000ml volumetric flask, 950ml water added, pH adjusted to 3.00 ± 0.03 with 1.5mol/L phosphoric acid solution and diluted to the mark with water, shake up) -acetonitrile (83: 20); mobile phase B: acetonitrile;
column temperature: 40 ℃;
detection wavelength: 200 nm;
flow rate: 0.27 ml/min;
sample introduction amount: 2.5 mul;
the elution gradient is shown in table 1, where the sugammadex sodium (8-substituent) retention time is between about 20.5min and 23.0min, the minor active ingredient 7-substituent is at about 0.65 times the main peak retention time, and the sugammadex sodium purity is calculated as the area and the calculation of 7-substituent and 8-substituent.
TABLE 1 elution gradiometer
Example 1
Adding sugammadex sodium (20.05g) into purified water (100ml) and stirring to dissolve; slowly adding ethanol (20ml) dropwise into the sugammadex sodium water solution, placing into a freeze dryer, and maintaining at-40 deg.C for 12 hr; after the curing is completed, opening the cold trap, vacuumizing, heating to-20 ℃ at the speed of 1 ℃/4min when the vacuum degree reaches 150mT, maintaining the temperature at-20 ℃ for 15 hours for sublimation drying, and finishing the drying; and continuously heating to 5 ℃ at the speed of 1 ℃/2min, maintaining for 15 hours at the temperature of 5 ℃ for desorption drying, closing a cold trap after drying is finished, and obtaining white crystal sodium sugammadex with the purity of 99.85 percent.
Example 2
Adding sugammadex sodium (20.03g) into purified water (90ml), and stirring to dissolve; slowly adding acetone (10ml) dropwise into the sugammadex sodium water solution, placing the solution into a freeze dryer, and maintaining the temperature at-30 ℃ for 15 hours; after the curing is completed, opening the cold trap, vacuumizing, heating to-15 ℃ at 1 ℃/3min when the vacuum degree reaches 150mT, maintaining the temperature at-15 ℃ for 20 hours for sublimation drying, and finishing the drying; and continuously heating to 0 ℃ at the speed of 1 ℃/3min, maintaining at 0 ℃ for 20 hours for desorption drying, closing the cold trap after drying is finished, and obtaining white crystal sodium sugammadex with the purity of 99.81 percent.
Example 3
Adding sugammadex sodium (20.06g) into purified water (100ml), and stirring to dissolve; slowly adding methanol (30ml) dropwise into the sugammadex sodium water solution, placing into a freeze dryer, and maintaining at-45 deg.C for 14 hr; after the curing is completed, opening the cold trap, vacuumizing, heating to-25 ℃ at the speed of 1 ℃/4min when the vacuum degree is 150mT, maintaining the temperature at-25 ℃ for 20 hours for sublimation drying, and finishing the drying; and continuously heating to 10 ℃ at the speed of 1 ℃/2min, maintaining at 10 ℃ for 15 hours for desorption drying, closing the cold trap after drying is finished, and obtaining white crystal sodium sugammadex with the purity of 99.80%.
Example 4
Adding sugammadex sodium (20.02g) into purified water (120ml), and stirring to dissolve; slowly dripping isopropanol (20ml) into the sugammadex sodium water solution, putting into a freeze dryer, and maintaining at-40 ℃ for 16 hours; after the curing is completed, opening the cold trap, vacuumizing, heating to-10 ℃ at 1 ℃/4min when the vacuum degree reaches 150mT, maintaining the temperature at-10 ℃ for 15 hours for sublimation drying, and finishing the drying; and continuously heating to 5 ℃ at the speed of 1 ℃/2min, maintaining for 15 hours at the temperature of 5 ℃ for desorption drying, closing a cold trap after drying is finished, and obtaining white crystal sodium sugammadex with the purity of 99.78%.
Example 5
Adding sugammadex sodium (20.03g) into purified water (100ml) and stirring to dissolve; slowly adding acetonitrile (20ml) dropwise into the sugammadex sodium water solution, placing the mixture into a freeze dryer, and maintaining the mixture at-40 ℃ for 10 hours; after the curing is completed, opening the cold trap, vacuumizing, heating to-20 ℃ at the speed of 1 ℃/4min when the vacuum degree reaches 150mT, maintaining the temperature at-20 ℃ for 15 hours for sublimation drying, and finishing the drying; and continuously heating to 10 ℃ at the speed of 1 ℃/2min, maintaining at 10 ℃ for 15 hours for desorption drying, closing the cold trap after drying is finished, and obtaining white crystal sodium sugammadex with the purity of 99.75%.
Example 6
Adding sugammadex sodium (20.07g) into purified water (80ml), and stirring to dissolve; slowly dropwise adding n-butanol (15ml) into the sugammadex sodium water solution, placing into a freeze dryer, and maintaining at-50 ℃ for 18 hours; after the curing is completed, opening the cold trap, vacuumizing, heating to-20 ℃ at 1 ℃/5min when the vacuum degree reaches 150mT, maintaining at-25 ℃ for 10 hours for sublimation drying, and finishing the drying; and continuously heating to 0 ℃ at the speed of 1 ℃/3min, maintaining at the temperature of 5 ℃ for 20 hours for desorption drying, closing a cold trap after drying is finished, and obtaining white crystal sodium sugammadex with the purity of 99.77%.
Confirmation of Crystal form Structure
The X-ray powder diffraction test instrument and the test conditions involved in the invention are as follows: x-ray powder diffractometer PANalytical E; Cu-K alpha; a sample stage: a flat plate; the incident light path is BBHD; diffraction light path: PLXCEL; voltage 45 kv and current 40 mA; a diverging slot 1/4; an anti-scatter slit 1; 0.04rad of cable pull slit; step length: 0.5 s; scanning range: 3 to 50 degrees. The characteristic peaks in the X-ray powder diffraction pattern (Cu-Ka) corresponding to the crystal form of sugammadex sodium are shown in the detailed chart 1 and the detailed chart 2.
Table 2 sugammadex crystal form N PXRD peaks
The samples of examples 1-6 all had the same X-ray powder diffraction pattern.
According to the existing reported preparation method of the sugammadex sodium crystal form, the sugammadex sodium in comparative examples 1-11 is prepared.
Comparative example 1
Adding sugammadex sodium (46g) into a mixed solution of purified water (69 ml)/methanol (69ml), stirring and dissolving at 25-35 ℃, adding activated carbon (11.5g), stirring at 25-35 ℃ for 30min, filtering, washing a filter cake with water (23 ml)/methanol (23ml), controlling the temperature of a filtrate to be 25-35 ℃, adding methanol (598ml), stirring for 2 hours, filtering, washing the filter cake with methanol (184ml), and drying at 55-60 ℃ for 14 hours to obtain crystalline sugammadex sodium, wherein the yield is 55.3% and the purity is 99.62%.
Comparative example 2
Adding sugammadex sodium (10.9g) into a mixed solution of purified water (15 ml)/methanol (15ml), adding activated carbon (2 g), filtering, and washing filter cake purified water (5 ml); and (3) controlling the temperature of the filtrate to be 50-55 ℃, adding methanol (135ml), stirring for 2 hours at 50-55 ℃, separating out solids, filtering, washing a filter cake with methanol (20ml), and drying for 24 hours at 70-75 ℃ in vacuum to obtain the amorphous sugammadex sodium, wherein the yield is 62.4%, and the purity is 99.53%.
Comparative example 3
Adding sugammadex sodium (5g) into purified water (10ml), stirring for dissolving, heating to 50-60 ℃, slowly dripping methanol (60ml), precipitating solid after adding, naturally cooling to room temperature, further cooling to 0-5 ℃, preserving heat for 1 hour, filtering, and drying to obtain crystalline sugammadex sodium, wherein the yield is 86.2%, and the purity is 99.64%.
Comparative example 4
Adding sugammadex sodium (10g) into purified water (20ml), stirring for dissolving, heating to 60 ℃, adding ethanol (120ml) while stirring, and separating out a large amount of white solid; naturally cooling to room temperature, further cooling to 0 ℃, keeping the temperature and stirring for 1 hour, performing suction filtration, and drying a filter cake to obtain crystalline sodium sugammadex with the yield of 88.4 percent and the purity of 99.56 percent.
Comparative example 5
Adding sugammadex sodium (10g) into purified water (20ml), stirring for dissolving, heating to 75 ℃, adding DMF (60ml) while stirring, and separating out a large amount of white solid; naturally cooling to room temperature, filtering, drying the filter cake to obtain crystalline sodium sugammadex with the yield of 88.7 percent and the purity of 99.62 percent.
Comparative example 6
Adding sugammadex sodium (10g) into purified water (20ml), stirring for dissolving, heating to 50 ℃, adding acetone (160ml) while stirring, and separating out a large amount of white solid; naturally cooling to room temperature, further cooling to 0 ℃, keeping the temperature and stirring for 1 hour, performing suction filtration, and drying a filter cake to obtain crystalline sodium sugammadex, wherein the yield is 87.3 percent, and the purity is 99.58 percent.
Comparative example 7
Adding sugammadex sodium (10g) into purified water (20ml), stirring to dissolve, placing the solution into a flat-bottom tray, placing the flat-bottom tray into a freeze dryer, pre-freezing to-80 ℃, then heating in a gradient manner, and performing freeze-drying for 24 hours to obtain the sugammadex sodium crystal with the purity of 99.34%.
Comparative example 8
Adding sugammadex sodium (10g) into purified water (50ml), stirring to dissolve, heating to 75 ℃ under stirring, stirring at the rotating speed of 200r/min, dropwise adding 1, 4-dioxane (300ml) into the solution, stirring to reduce the temperature to room temperature, separating out a large amount of white solids, performing suction filtration, and drying a filter cake in vacuum to dryness to obtain the amorphous sugammadex sodium, wherein the yield is 90.8%, and the purity is 99.66%.
Comparative example 9
Adding sugammadex sodium (10g) into purified water (30ml), stirring and dissolving to obtain a sugammadex sodium water solution; DMF (75ml) was added to an aqueous solution of sugammadex sodium to crystallize, and after crystallization at 25 ℃ for 1 hour with stirring, the crystal was filtered, and the filter cake was washed with a mixed solution of water/DMF (20 ml. times.2), whereby crystalline sugammadex sodium was obtained in a yield of 86.7% and a purity of 99.58%.
Comparative example 10
Crystalline sodium sugammadex was prepared according to the preparation method of comparative example 9, and the crystalline sodium sugammadex prepared (93g) was added to purified water (3ml), followed by addition of methanol (480 ml); heating the reaction liquid to 65 ℃ to ensure that the reaction liquid becomes clear, and slowly cooling; cooling to 42-45 ℃, keeping the temperature, stirring for 2 hours, and crystallizing; the reaction solution is continuously cooled to 25 ℃, kept at 25 ℃, stirred and crystallized for 2 hours, filtered, and the filter cake is washed by a water/methanol (20ml multiplied by 2) mixed solution to obtain the crystalline sodium sugammadex, the yield is 80.2 percent, and the purity is 99.62 percent.
Comparative example 11
Crystalline sodium sugammadex (5g) prepared in comparative example 10 was heated to 80-90 ℃ under vacuum (15mmHg) and dried for 12 hours to obtain crystalline sodium sugammadex with a purity of 99.64%.
Heat stability test
The sugammadex sodium prepared in example 1 and comparative examples 1 to 11 were dissolved in water, and then stored in the dark at 25 ℃ for 6 months, and samples were taken for 1 month, 3 months and 6 months to measure the impurity content, and the purity of sugammadex sodium was measured by HPLC. The results are shown in Table 3.
TABLE 3 stability test results of sugammadex sodium solution
As shown in table 3, the stability test results of the sugammadex sodium solution stored in the dark at 25 ℃ show that the impurities of the amorphous sugammadex sodium of comparative example 2 and comparative example 8 are significantly increased, and the impurities are more than 1% after 3 months stability test; after the crystal forms of other comparative examples are inspected for 6 months, the results show that the impurities are all more than 0.5; the stability test result of the sugammadex sodium crystal form solution shows that the impurity change is not obvious and is basically stable; the examination shows that the examples 1 to 6 of the invention have similar stability test results.
The sugammadex sodium prepared in example 1 and comparative examples 1 to 11 were subjected to accelerated testing in the dark at 40 ℃ (RH 45%) for 6 months, and samples were taken at 1 month, 3 months, and 6 months, respectively, for impurity content, and were tested by the purity measurement method for sugammadex sodium by HPLC. The results are shown in Table 4.
Table 4 results of accelerated test at 40 ℃ in solid state of sugammadex sodium
The solid stability test result shows that the impurities of the amorphous sugammadex sodium in the comparative examples 2 and 8 are obviously increased, and after 3-month stability test, the impurities are more than 1 percent; after the crystal forms of other comparative examples are inspected for 6 months, the results show that the impurities are all more than 0.5; the test result of the crystal form solid stability of sugammadex sodium shows that the impurity change is not obvious and is basically stable; the examination shows that the examples 1 to 6 of the invention have similar stability test results.
Light stability test
The sugammadex sodium prepared in example 1 and comparative examples 1 to 11 were respectively taken, and the impurity content was measured and detected under strong light irradiation (4500Lx ± 500Lx) for 0, 15 and 30 days, respectively, and the purity measurement method of sugammadex sodium was referred to HPLC. The results are shown in Table 5.
TABLE 5 light stability test results for sugammadex sodium
The photostability test result shows that under the condition of strong light irradiation, the crystal form impurities of the sugammadex sodium are not obviously changed, the light irradiation stability is good, and the dosage form prepared by utilizing the crystal form is beneficial to medicine storage and ensures the medicine effect; the results of the sodium amorphous sugammadex illumination test of comparative example 2 and comparative example 8 show that the impurities are significantly increased and the photostability is poor; the examination shows that the examples 1 to 6 of the invention have similar light stability test results.
Clarity and color test
The sugammadex sodium prepared in example 1 and comparative examples 1-11 were subjected to accelerated testing at 40 ℃ in the dark for 6 months, and samples were taken at the initial stage, 1 month, 3 months, and 6 months to determine clarity and color of the sample solutions. Referring to the registration label of sugammadex sodium injection (JX20140183), the clarity detection of a sample solution refers to "0902 of the general rules of the four departments of the chinese pharmacopoeia 2015 edition"; and (3) detecting the color of the sample solution, and measuring the absorbance (which should be less than 0.75) at the wavelength of 350nm by using ultra pure water as a blank solution and adopting an ultraviolet-visible spectrophotometry (0401 in the fourth part of the pharmacopoeia 2015). The results are shown in Table 6.
TABLE 6 results of accelerated test at 40 ℃ in the solid state of sugammadex sodium
After the sugammadex crystal form is inspected for 6 months, the clarity is less than 0.5 turbidity, the color detection absorbance is less than 0.75, and the sugammadex crystal form reaches the raw material drug standard of injection. Examination found that inventive examples 1-6 had similar clarity and color test results.
Claims (10)
1. The sugammadex crystal form is characterized in that the sugammadex crystal form uses Cu-Kalpha radiation, and an X-ray diffraction spectrum expressed by 2 theta has characteristic peaks at 4.49 +/-0.2 degrees, 5.47 +/-0.2 degrees, 7.20 +/-0.2 degrees, 9.96 +/-0.2 degrees, 10.24 +/-0.2 degrees, 15.75 +/-0.2 degrees and 17.57 +/-0.2 degrees.
2. The sugammadex crystal form of claim 1, wherein the sugammadex crystal form has characteristic peaks at 4.49 ± 0.2 °, 5.47 ± 0.2 °, 7.20 ± 0.2 °, 7.77 ± 0.2 °, 8.80 ± 0.2 °, 9.96 ± 0.2 °, 10.24 ± 0.2 °, 12.54 ± 0.2 °, 15.75 ± 0.2 °, 16.28 ± 0.2 °, 16.85 ± 0.2 °, 17.59 ± 0.2 °, 18.06 ± 0.2 °, 19.16 ± 0.2 ° in an X-ray diffraction pattern expressed in terms of 2 Θ using Cu-ka radiation.
3. The crystalline form of sugammadex sodium of claim 1, wherein said crystalline form has an X-ray powder diffraction pattern as shown in figure 1.
4. A process for preparing the crystalline form of sugammadex sodium according to any one of claims 1 to 3, characterized in that the preparation process comprises the following steps:
adding sugammadex sodium into purified water, stirring and dissolving to obtain a sugammadex sodium aqueous solution; slowly dripping an organic solvent A into the sodium sugamide aqueous solution, placing the sodium sugamide aqueous solution into a freeze dryer for pre-freezing, opening a cold trap after solidification, vacuumizing, slowly heating to a certain temperature for the first time, maintaining the temperature for sublimation drying, and finishing drying; slowly raising the temperature to a certain temperature for the second time, maintaining the temperature for analysis and drying, and closing the cold trap after drying to obtain white crystal sodium sulgamide.
5. The method for preparing sugammadex sodium crystal form according to claim 4, wherein the mass volume ratio of sugammadex sodium to purified water is 1: 4-6 g/ml.
6. The process for preparing sugammadex sodium crystalline form according to claim 4, wherein the organic solvent A is one or two of methanol, ethanol, isopropanol, acetone, n-butanol, acetonitrile; the mass-volume ratio of the sugammadex sodium to the organic solvent A is 1: 0.5-1.5, and g/ml.
7. The method for preparing sugammadex sodium crystalline form according to claim 4, characterized in that the prefreezing temperature is between-50 and-30 ℃; the pre-freezing maintaining time is 10-18 hours.
8. The method for preparing sugammadex sodium crystal form according to claim 4, characterized in that the first slow temperature rise is from-25 to-10 ℃; the heating rate is 1 ℃/3-5 min.
9. The method for preparing sugammadex sodium crystalline form according to claim 4, characterized in that the second slow warming is to 0-10 ℃; the heating rate is preferably 1 ℃/2-3 min.
10. Use of the crystalline form of sugammadex sodium according to any of claims 1 to 3 as active ingredient for the preparation of a muscle relaxant antagonist medicament.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910928446.3A CN112574330B (en) | 2019-09-28 | 2019-09-28 | Shugansu sodium crystal form |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910928446.3A CN112574330B (en) | 2019-09-28 | 2019-09-28 | Shugansu sodium crystal form |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN112574330A true CN112574330A (en) | 2021-03-30 |
| CN112574330B CN112574330B (en) | 2023-06-06 |
Family
ID=75110283
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910928446.3A Active CN112574330B (en) | 2019-09-28 | 2019-09-28 | Shugansu sodium crystal form |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN112574330B (en) |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107778383A (en) * | 2016-08-24 | 2018-03-09 | 王炳永 | A kind of process for purification for the more glucose sodium that relaxes |
| CN107892727A (en) * | 2017-11-27 | 2018-04-10 | 合肥博思科创医药科技有限公司 | A kind of purification process for the more glucose sodium that relaxes |
| CN108929389A (en) * | 2017-05-23 | 2018-12-04 | 合肥博思科创医药科技有限公司 | A kind of environmentally protective easypro more glucose sodium preparation method |
| CN108929390A (en) * | 2017-05-23 | 2018-12-04 | 合肥博思科创医药科技有限公司 | A kind of method that microwave reaction synthesizes the more glucose sodium that relaxes |
| CN109053933A (en) * | 2018-08-01 | 2018-12-21 | 合肥博思科创医药科技有限公司 | A kind of preparation method of the unformed more glucose sodium that relaxes |
| TW201912656A (en) * | 2017-08-23 | 2019-04-01 | 台耀化學股份有限公司 | Method for preparing sugammadex sodium and crystalline form thereof |
| CN110615860A (en) * | 2018-06-20 | 2019-12-27 | 江苏恒瑞医药股份有限公司 | Method for purifying sugammadex sodium |
-
2019
- 2019-09-28 CN CN201910928446.3A patent/CN112574330B/en active Active
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107778383A (en) * | 2016-08-24 | 2018-03-09 | 王炳永 | A kind of process for purification for the more glucose sodium that relaxes |
| CN108929389A (en) * | 2017-05-23 | 2018-12-04 | 合肥博思科创医药科技有限公司 | A kind of environmentally protective easypro more glucose sodium preparation method |
| CN108929390A (en) * | 2017-05-23 | 2018-12-04 | 合肥博思科创医药科技有限公司 | A kind of method that microwave reaction synthesizes the more glucose sodium that relaxes |
| TW201912656A (en) * | 2017-08-23 | 2019-04-01 | 台耀化學股份有限公司 | Method for preparing sugammadex sodium and crystalline form thereof |
| CN107892727A (en) * | 2017-11-27 | 2018-04-10 | 合肥博思科创医药科技有限公司 | A kind of purification process for the more glucose sodium that relaxes |
| CN110615860A (en) * | 2018-06-20 | 2019-12-27 | 江苏恒瑞医药股份有限公司 | Method for purifying sugammadex sodium |
| CN109053933A (en) * | 2018-08-01 | 2018-12-21 | 合肥博思科创医药科技有限公司 | A kind of preparation method of the unformed more glucose sodium that relaxes |
Also Published As
| Publication number | Publication date |
|---|---|
| CN112574330B (en) | 2023-06-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011515472A (en) | A novel solid form of bendamustine hydrochloride | |
| JP2000512992A (en) | Polymorphic compound | |
| KR102522895B1 (en) | Crystal Form of JAK Kinase inhibitor Bisulfate and a preparation method therefor | |
| AU2017373239B2 (en) | Crystalline forms of a bromodomain and extraterminal protein inhibitor drug, processes for preparation thereof, and use thereof | |
| CN112538124A (en) | Crystal form of sugammadex sodium | |
| EA019689B1 (en) | 2-[[[2-[(hydroxyacetyl)amino]-4-pyridinyl]methyl]thio]-n-[4-(trifluoromethoxy)phenyl]-3-pyridinecarboxamide benzenesulfonate, crystals and polymorphs thereof, and processes for production thereof | |
| CN112538123A (en) | Crystal form M of sugammadex sodium | |
| SK186699A3 (en) | Crystalline macrolides and process for their preparation | |
| CA3051146A1 (en) | Crystal form of gft-505 and preparation method and use thereof | |
| MXPA04009009A (en) | Isostructural pseudopolymorphs of 9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin a. | |
| US20200181064A1 (en) | Pharmaceutically acceptable salts of fatty acids | |
| CN106892900A (en) | A kind of Vonoprazan fumarate and preparation method thereof | |
| US10004750B2 (en) | Salt of cephalosporin derivative, its crystalline solid and a method of manufacturing thereof | |
| CN112574330A (en) | Crystal form of sugammadex sodium | |
| ES2926790T3 (en) | Sodium-glucose transporter inhibitor diethylamine solvate, and method of preparation and application thereof | |
| AU2016236659B9 (en) | AHU377 crystal form, preparation method and use thereof | |
| CN104910147B (en) | Eliquis crystal and preparation method thereof | |
| US20160122274A1 (en) | Salts of Sitagliptin, Process from the Preparation and Pharmaceutical Composition Therefore | |
| EP3473623B1 (en) | Crystal forms of nbi-98854, preparation method therefor and use thereof | |
| ES2778434T3 (en) | Supersaturated Compositions of Benzimidazole Compounds | |
| US10561667B2 (en) | Orbit azine-fumarate, hydrate, crystal form and preparation method therefor | |
| WO2017028762A1 (en) | Crystal form of naphthalene cyclic compound | |
| TWI707851B (en) | Novel crystals of piperazine compounds | |
| CN106336363A (en) | Safinamide mesylate crystal form C and preparation method thereof | |
| CA2944150A1 (en) | Polymorphic forms and co-crystals of a c-met inhibitor |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |